Advertisement

Studies Confirm and Extend the Benefits of Ixazomib in Multiple Myeloma

Patients with multiple myeloma now have access to an all-oral regimen, with the recent approval of the oral proteasome inhibitor ixazomib (Ninlaro) in previously treated patients. 

 The ASCO Post

click me